Navigation Links
OncoSec Announces Leadership Team Appointments
Date:5/11/2011

SAN DIEGO, May 11, 2011 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a therapeutic oncology company developing innovative medical approaches to treat solid tumor cancers that have unmet medical needs, announced today the appointment of three members to its leadership team. Formed earlier this year, OncoSec expects to initiate Phase II clinical trials for its tumor-destroying, tissue-sparing ElectroOncology therapies before the end of this year.

(Logo:  http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

OncoSec's novel targeted tumor therapies are designed to address the drawbacks of conventional therapies by being tissue sparing; providing potential functional, cosmetic and quality of life benefits; being less invasive and reducing side effects; and potentially reducing both treatment and post-treatment costs. Based on extensive past validating data from human studies, OncoSec expects to initiate advanced stage clinical studies for its ElectroImmunotherapy and ElectroChemotherapy programs.

It is estimated that half of the 1.4 million cancers diagnosed each year in the United States are solid-tumor cancers.  Cancers of the lung, prostate, colon, rectum or breast cancer are all solid tumor cancers. The National Institutes of Health estimated the annual cost of cancer to be $228.1 billion in 2008.

Today, Punit Dhillon, OncoSec's co-founder, President and CEO, announced the following management appointments:

Dr. Michael Cross, Chief Business Officer

Michael Cross, PhD, a co-founder of OncoSec, will serve as Chief Business Officer. He will be responsible for business development, engineering operations, partnerships and fundraising, among other duties. Dr. Cross, who holds an MBA, has nearly two decades of life sciences venture capital and biotech industry experience. Prior to joining OncoSec, Dr. Cross was Vice President at Growt
'/>"/>

SOURCE OncoSec Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoSec Medical Featured in Medical Device Daily
2. OncoSec Medical Appoints Punit Dhillon as President and CEO
3. Brainlab Announces FDA 510(k) Clearance for New HybridArc™ Software for Radiosurgery
4. Mtech Announces Winners of the 2011 University of Maryland $75K Business Plan Competition
5. PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015
6. Advanced Cell Technology Announces 2011 First Quarter Results
7. Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
8. Cell Biosciences Announces Issuance of Three US Patents
9. Cord Blood America Announces BioCells, Inc., Which it Acquired in 2010, is Opening Office in Miami, Florida and 5 New Offices in Argentina Soon
10. Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
11. Cord Blood America Announces Reverse Stock Split Takes Effect Monday, May 9, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Grade school history lessons often have it that American ... whooping cough, chicken pox, influenza and tuberculosis brought to ... while estimates vary, about 20 million people lived in ... percent of them were killed by European diseases., But ... Arizona State University and Johannes Krause of the University ...
(Date:8/20/2014)... August 20, 2014 High performance ... apply the most complete climate and Earth system ... climate change issues. , Eight national laboratories, including ... the National Center for Atmospheric Research, four academic ... effort. Other participating national laboratories include Argonne, Brookhaven, ...
(Date:8/20/2014)... CA (PRWEB) August 20, 2014 The ... is being held on October 29-30 in San ... from industry, academic and government researchers and clinicians focused ... the space. , In the twelve years since ... hundred therapies have been introduced with pharmacogenetic information in ...
(Date:8/20/2014)... could improve the health of your heart, researchers have ... used a standard TENS machine like those designed to ... tragus, the small raised flap at the front of ... , The stimulation changed the influence of the nervous ... that can drive failing hearts too hard. , Professor ...
Breaking Biology Technology:Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 36th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2'Tickling' your ear could be good for your heart 2
... , SHANGHAI, Nov. 24 /PRNewswire-Asia/ ... (SFDA) has approved the,investigational new drug application (IND) for its ... This IND,approval allows Biolaxy to initiate its first phase I ... disorder characteristic of high blood glucose and poor,metabolism. The complications ...
... Primary efficacy endpoint has been met for ... , QUEBEC CITY, Nov. 24 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. ... biopharmaceutical company focused on endocrine therapy and oncology, today announced ... targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with ...
... DIEGO, Nov. 24, 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ... present at the Piper Jaffray 21st Annual Health Care Conference on ... Time) at the New York Palace Hotel in New York City. ... provide an overview of the company, including its clinical development and ...
Cached Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3
(Date:8/21/2014)... Mller the Fram Strait is a key region in the ... between Greenland and Svalbard warm Atlantic water flows to the ... cold Arctic water masses and sea ice push their way ... portion of the Atlantic water cools here on its way ... of the water caused in this manner drives the global ...
(Date:8/21/2014)... Wednesday, Oct. 18-22, 2014 , WHERE: , ... San Diego, CA 92101 , WHAT: , ... of the latest research in human genetics. Examples ... high-scoring abstracts on rare genetic variants in health ... treatment for sun sensitivity (Saturday, Oct. 18, 5:30-7:30 ...
(Date:8/21/2014)... feeding tube connectors, designed by an international standards process, ... , According to an invited review published in the ... ( NCP ), the official journal of the American ... connectors will greatly reduce the occurrence of misconnection that ... Small-bore connectors, which are used to join medical devices, ...
Breaking Biology News(10 mins):Arctic sea ice influenced force of the Gulf Stream 2Arctic sea ice influenced force of the Gulf Stream 3American Society of Human Genetics 2014 Annual Meeting 2New feeding tube connectors will improve patient safety 2
... review of the principles and management implications of nitrogen ... new monograph Nitrogen in Agricultural Systems . The ... Crop Science Society of America (CSSA), and the Soil ... 30 leading experts to holistically address nitrogen in the ...
... biomedical engineering assistant professor at The University of ... million National Institutes of Health/National Cancer Institute grant ... James Tunnell says the five-year project will include ... Anderson Cancer Center in Houston and the University ...
... In a move that promises to change the economics of ... set of techniques for cleanly converting problematic biofuels waste into ... available online in the journal Metabolic Engineering . The ... new fermentation process that allows E. coli and ...
Cached Biology News:Nitrogen: Nutrient of life 2Research yields pricey chemicals from biodiesel waste 2Research yields pricey chemicals from biodiesel waste 3
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Mfr ...
A cost-effective serum for general cell growth requirements. All serum is collected from calves aged 10 days old or less....
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... cell culture scale-up, these culture chambers produce ... 10 9 range and are useful ... flasks. • High mechanical • strength and ... to shipping • Certified nonpyrogenic and sterilized ...
Biology Products: